Published 9 hours ago

HC Wainwright Reiterates Buy Rating for Dynavax Technologies (NASDAQ:DVAX)

Summary by modernreaders.com

HC Wainwright restated their buy rating on shares of Dynavax Technologies (NASDAQ:DVAX – Free Report) in a research note released on Tuesday morning, Benzinga reports. They currently have a $29.00 target price on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Dynavax Technologies’ FY2026 earnings at $0.32 EPS. Separately, The Goldman Sachs Group cut their target price on shares of Dynavax Technologies from $20.0…

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center0Last Updated5 hours agoBias Distribution

No sources with tracked biases.

Bias Distribution

There is no tracked Bias information for the sources covering this story.

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

HC Wainwright Reiterates Buy Rating for Dynavax Technologies (NASDAQ:DVAX)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics